Expert Interviews

Shared insight on key factors that determine the best selection of therapy in patients with relapsed/refractory multiple myeloma, with a focus on bispecific antibodies and CAR T-cell therapy.

After reviewing their third patient case, expert hematologist-oncologists highlight the treatment armamentarium for relapsed/refractory multiple myeloma.

Peter Voorhees, MD, starts a conversation on the best treatment options for patients with multiple myeloma after relapse.

Heather McArthur, MD, presents the case of a 69-year-old woman with stage II HER2+ mBC for discussion.

Dr Bekaii-Saab provides an overview of the first-line treatment options in metastatic colorectal cancer, and the factors that impact treatment decision-making.

Tanios Bekaii-Saab, MD, explains the barriers to molecular testing for patients with metastatic colorectal cancer, and how they can be addressed.

A panel of expert oncologists consider how HER2 expression can positively impact the selection of targeted therapies for patients with metastatic colorectal cancer.

Expert perspectives on the PARADIGM study, which highlighted the role of panitumumab in combination with frontline chemotherapy in patients with left-sided, RAS wild-type metastatic colorectal cancer.

Closing out their discussion on adverse event management in advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, consider overlapping toxicity in TKI/IO regimens.

Expert perspectives on the most common adverse events seen while managing advanced renal cell carcinoma, followed by advice on how best to manage these and counsel patients.

Expert oncologists highlight remaining unmet needs in the setting of metastatic triple-negative breast cancer and look toward future evolutions in care.

Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.

An expert from the University of Texas Southwestern Medical Center in Dallas describes the efficacy of stereotactic radiation in the treatment of patients with metastatic kidney cancer.

An expert from the University of Texas Southwestern Medical Center in Dallas gives an overview of the multimodal use of stereotactic radiation for the treatment of patients with metastatic kidney cancer.

An expert from the University of Texas Southwestern Medical Center in Dallas emphasized that stereotactic radiation provides oncologists with an alternative modality for treating patients with kidney cancer for whom standard ablative surgery is not an option.

With the increasing clinical use of circulating tumor DNA biomarker testing among community urologists, an expert from Tisch Cancer Institute at Mount Sinai in New York City suggests that more prospective data are needed to make the best decisions among patients with bladder cancer.

Sascha Tuchman, MD, discusses how frail patients with multiple myeloma are defined in his clinical practice, and what assessment models he utilizes.

Dr Sascha Tuchman explains how he measures an adequate or successful frontline treatment response in patients with transplant-ineligible NDMM.

Before closing out their module on transplant-ineligible newly diagnosed multiple myeloma, panelists reflect on best treatment practices in the setting of high-risk disease.

Practical perspectives on the optimal selection of therapy for transplant-ineligible NDMM, followed by considerations for duration of therapy and dosing.